Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Ono Pharmaceutical Ltd

4528
Current price
1 815.5 JPY -3.95 JPY (-0.22%)
Last closed 1 809 JPY
ISIN JP3197600004
Sector Healthcare
Industry Drug Manufacturers - General
Exchange Tokyo Stock Exchange
Capitalization 852 754 890 789 JPY
Yield for 12 month -32.38 %
1Y
3Y
5Y
10Y
15Y
4528
21.11.2021 - 28.11.2021

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan. Address: 8-2, Kyutaromachi 1-chome, Osaka, Japan, 541-8564

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

327 902.62 JPY

P/E ratio

8.993

Dividend Yield

4.7 %

Current Year

+502 671 999 996 JPY

Last Year

+447 187 000 068 JPY

Current Quarter

+122 663 999 940 JPY

Last Quarter

+117 675 000 010 JPY

Current Year

+375 545 999 962 JPY

Last Year

+337 125 000 014 JPY

Current Quarter

+95 457 999 982 JPY

Last Quarter

+88 003 999 996 JPY

Key Figures 4528

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 137 187 999 672 JPY
Operating Margin TTM 20.54 %
PE Ratio 8.993
Return On Assets TTM 7.67 %
PEG Ratio
Return On Equity TTM 12.11 %
Wall Street Target Price 327 902.62 JPY
Revenue TTM 484 297 998 336 JPY
Book Value 1 665.85 JPY
Revenue Per Share TTM
Dividend Share 80 JPY
Quarterly Revenue Growth YOY -11.6 %
Dividend Yield 4.7 %
Gross Profit TTM 267 850 000 000 JPY
Earnings per share 201.88 JPY
Diluted Eps TTM 201.88 JPY
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY -59.4 %
Profit Margin 19.64 %

Dividend Analytics 4528

Dividend growth over 5 years

81 %

Continuous growth

3 years

Payout Ratio 5 years average

36 %

Dividend History 4528

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 80
Ex Dividend Date 28.03.2025
Forward Annual Dividend Yield 4.41 %
Last Split Factor 5:1
Payout Ratio 39.62 %
Last Split Date 29.03.2016
Dividend Date

Stock Valuation 4528

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 8.993
Forward PE 13.947
Enterprise Value Revenue 1.7206
Price Sales TTM 1.7608
Enterprise Value EBITDA 5.9177
Price Book MRQ 1.0898

Financials 4528

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators 4528

For 52 weeks

1 809 JPY 2 747.37 JPY
50 Day MA 1 953.82 JPY
Shares Short Prior Month
200 Day MA 2 218.57 JPY
Short Ratio
Shares Short
Short Percent